MedTrace Logo

Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00003665 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-02-28

No results posted yet for this study

Summary

Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV melanoma. Vaccines may make the body build an immune response to kill tumor cells.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

dendritic cell-MART-1 peptide vaccine

BIOLOGICAL

gp100 antigen

BIOLOGICAL

therapeutic tumor infiltrating lymphocytes

BIOLOGICAL

tyrosinase peptide

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Brian J. Czerniecki, MD, PhD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-04-30
Primary Completion
2002-10-31
Completion
2002-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003665 on ClinicalTrials.gov